已知治疗2型糖尿病的胰高血糖素样肽1受体激动剂与收缩压轻度降低及心率增加有关。但基于临床测定的结果不能充分评估一种药物的24h药代动力学作用。该研究采用动态血压监测评估每周一次胰高血糖素样肽1受体激动剂dulaglutide对血压和心率的作用。方法:纳入755例[年龄(56±10)岁,81%为白人,48%为女性]服用口服降糖药≥1种,诊室血压为90~140/60~90mm Hg(1mm Hg=0.133kPa)之间的2型糖尿病患者随机接受dulaglutide(1.5或0.75mg)或安慰剂皮下注射26周。在基线,4、16、26周时监测动态血压。主要观察指标为从基线到16周时24h平均收缩压的改变,比较dulaglutide与安慰剂 Glucagon-like peptide 1 receptor agonists known to treat type 2 diabetes are associated with mildly reduced systolic blood pressure and increased heart rate. However, based on the results of clinical assays, the 24 h pharmacokinetic effect of a drug can not be adequately evaluated. The study used ambulatory blood pressure monitoring to assess the effect of weekly glucagon-like peptide 1 receptor agonist dulaglutide on blood pressure and heart rate. METHODS: A total of 755 patients (56 ± 10 years of age, 81% of whites and 48% of females) were enrolled in this study. Oral hypoglycemic agents were administered in ≥1 and blood pressure was 90 to 140/60 to 90 mm Hg (1 mm Hg = 0.133 kPa) ) Patients with type 2 diabetes were randomized to receive either dulaglutide (1.5 or 0.75 mg) or placebo for 26 weeks. Ambulatory blood pressure was monitored at baseline, 4, 16, 26 weeks. MAIN OUTCOME MEASURES 24-h average systolic blood pressure change from baseline to 16 weeks, comparing dulaglutide with placebo